Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients

Vista sencilla de ítem
dc.citation.titleFuture Oncologyes
dc.creatorPerroud, Herman A
dc.creatorRico, María José
dc.creatorAlasino, Carlos María
dc.creatorQueralt, Francisco 
dc.creatorMainetti, Leandro Ernesto
dc.creatorPezzotto, Stella Maris
dc.creatorRozados, Viviana R.
dc.creatorScharovsky, O. Graciela
dc.date.accessioned2018-05-07T12:43:51Z
dc.date.available2018-05-07T12:43:51Z
dc.date.issued2013-03-08
dc.descriptionMetronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs, without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our pre-clinical results suggested that combined MCT with cyclophosphamide (CY) and celecoxib (CEL) could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of the oral chronic administration of CY 50 mg p.o. daily, plus CEL 400 mg (200 mg p.o. bid) in advanced breast cancer patients (ABCP). The therapeutic response consisted in stable disease in a high proportion of patients and one partial response. The overall clinical benefit rate obtained was 66.7%. Toxicity was low. Evaluation of quality of life showed no changes during the response period. MCT with CY + Cel is safe and shows therapeutic effect in ABCP.es
dc.description.filFil: Perroud, Herman A. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentinaes
dc.description.filFil: Rico, María José. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentinaes
dc.description.filFil: Alasino, Carlos María. Institute of Oncology of Rosario; Argentinaes
dc.description.filFil: Queralt, Francisco. Institute of Oncology of Rosario; Argentinaes
dc.description.filFil: Pezzotto, Stella Maris. Research Council of the National University of Rosario (CIUNR); Argentinaes
dc.description.filFil: Rozados, Viviana R. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentinaes
dc.description.filFil: Scharovsky, O. Graciela. Universidad Nacional de Rosario. Consejo de Investigaciones UNR, Facultad de Ciencias Médicas; Argentinaes
dc.formatapplication/pdf
dc.format.extent1-27es
dc.identifier.issn1744-8301es
dc.identifier.urihttp://hdl.handle.net/2133/11302
dc.language.isoenges
dc.publisherFuture Medicine Ltdes
dc.relation.publisherversionhttps://doi.org/10.2217/fon.12.196es
dc.rightsopenAccesses
dc.rights.holderAutoreses
dc.rights.holderFuture Medicine Ltdes
dc.rights.textFuture Medicine Ltd y sus licenciantes poseen los derechos de autor de todo el material contenido en este sitio. Ningún material puede revenderse o publicarse en otro lugar sin el consentimiento por escrito, salvo que lo autorice una licencia de Future Medicine Ltd o en la medida en que lo exija la ley aplicable.es
dc.subjectBreast canceres
dc.subjectBiomarkerses
dc.subjectMetronomic chemotherapyes
dc.subjectCyclophosphamidees
dc.subjectCelecoxibes
dc.titleSafety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patientses
dc.typearticle
dc.typeartículo
dc.typeacceptedVersion
dc.type.collectionarticulo
dc.type.versionacceptedVersiones

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Future Oncol 9 (3)451-62, 2013.pdf
Tamaño:
621.64 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
Nombre:
license.txt
Tamaño:
3.59 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

CIUNR - Ciencias Naturales - Artículos de Revista
FCM - SCTeI - Artículo de Revista de Investigación
FCM - Instituto de Genética Experimental - Artículos